Skip to navigation | Skip to main content | Skip to footer
Menu Search the University of Manchester siteSearch
Search type

Alternatively, use our A–Z index

Dr Andrew Clamp - publications

List of publications


  • McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M, Hall G, Clamp A, Earl H, Banerjee S, Kristeleit R, Raja F, Feeney A, Lawrence C, Dawson-Athey L, Persic M, Khan I. (2014). A randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Ann Oncol, 25(10), 1988-1995. eScholarID:253669 | DOI:10.1093/annonc/mdu363
  • Conway A, Clamp AR, Hasan J, Goonetilleke D, Shore K, Wong LM, Wong J, Jayson GC. (2014). Accessing Cancer Services in North West England:the Chinese population. E C C, 23, 570-581. eScholarID:253779 | DOI:10.1111/ecc.12171
  • Khoja L, Kumaran G, Zee YK, Murukesh N, Swindell R, Saunders MP, Clamp AR, Valle JW Wilson G, Jayson GC, Hasan J. (2014). Evaluation of hypertension and proteinuria as markers of efficacy in anti-angiogenic therapy for metastatic colorectal cancer. J Clin Gastroenterol, 48, 430-434. eScholarID:253784 | DOI:10.1097/MCG.0b013e3182a8804c
  • Clamp A, Jayson G. (2014). PARP inhibitors in BRCA-mutation associated ovarian cancer. Lancet Oncol, eScholarID:253716 | DOI:10.1016/S1470-2045(2014)71172-6
  • Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, Bannoo S, Scherer SJ, Banks RE, Dive C, Jayson GC. (2014). The combination of circulating Ang-1 and Tie-2 levels predicts progression-free survival advantage in bevacizumab treated patients with ovarian cancer. Clin Cancer Res, 20(17), 4549-4558. eScholarID:253707 | DOI:10/1150/1076-0432.CCR-13-3248
  • Metcalf RL, Fry DJ, Swindell R, McGurk A, Clamp AR, Jayson GC, Hasan J. (2014). Thrombosis in ovarian cancer: a case control study. British Journal of Cancer Management, eScholarID:220127 | DOI:10.1038/bjc.2014.3


  • Horsley L, Cummings J, Middleton M, Ward T, BAcken A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC. (2013). A phase I trial of intravenous 4(N-(S-glutathionylacetyl)amino)penylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemother Pharmacol, 72, 1343-1352. eScholarID:253792 | DOI:10.1007/s00280-013-2320-9
  • Shaw D, Clamp A, Jayson GC. (2013). Angiogenesis as a target for the treatment of ovarian cancer. Curr Opin Oncol, 25, 558-565. eScholarID:253807 | DOI:10.1097/CCO.0b013e328363e0da


  • Quinn AM, Blackhall F, Wilson G, Danson S, Clamp A, Ashcroft L, Brierley J, Hasleton P. (2012). Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics. Histopathology, 61, 454-464. eScholarID:199959


  • O'Connor JPB, Rose CJ, Jackson A, Watson Y, Cheung S, Maders F, Whitcher BJ, Roberts C, Buonacorssi GA, Thompson G, Clamp AR, Jayson GC, Parker GJ. (2011). DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer, 105, 139-145. eScholarID:152021 | DOI:10.1038/bjc.2011.191
  • Clamp A. (2011). Endometrial cancer: what have the clinical trials taught us?. In Kehoe S, Edmondson RJ, Gore M, McNeish IA (Ed.), Gynaecological Cancer: Biology and therapeutics. (pp. 153-166). London: RCOG Press. eScholarID:152040
  • Griffiths RW, Zee YK, Evans S, Mitchell CL, Kumaran GC, Welch RS, Jayson GC, Clamp AR, Hasan J. (2011). Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of ovary, peritoneum and fallopian tube. Int J Gynecol Cancer, 21(1), 58-65. eScholarID:152028 | DOI:10.1097/IGC.0b013e3182049273
  • Sabharwal A, Waters R, Danson S, Clamp A, Lorigan P, Thatcher N, Margison GP, Middleton MR. (2011). Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res, 21, 502-508. eScholarID:1d20887 | DOI:10.1097/CMR.0b013e32832ccd58


  • Kumaran GC, Jayson GC, Clamp AR. (2009). Antiangiogenic drugs in ovarian cancer. Br J Cancer, 100(1), 1-7. eScholarID:1d32387 | DOI:10.1038/sj.bjc.6604767


  • Clamp, A, Schoffski, P, Valle, J, Wilson, R, Marreaud, S, Govaerts, A, Debois, M, Lacombe, D, Twelves, C, Chick, J, Jayson, G, NULL. (2008). A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol, 61(4), 579-585. eScholarID:1d31262 | DOI:10.1007/s00280-007-0509-5
  • Clamp AR, Jayson GC. (2008). The role of imaging in the clinical development of anti-angiogenic agents. In Teicher BV, Ellis L (Ed.), Antiangiogenic agents in cancer therapy. Humana Press. eScholarID:152047
  • Rosa DD, Clamp AR, Jayson GC. (2008). Tumours of the ovary and fallopian tube. In Price P, Sikora K, Illidge T (Ed.), Treatment of cancer. (pp. 748-763). London: Hodder Arnold. eScholarID:152053


  • Backen A, Cole C, Lau S, Clamp A, McVey R, Gallagher JT, Jayson GC. (2007). Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer, 96(10), 1544-1548. eScholarID:1d31280 | DOI:10.1038/sj.bjc.6603747
  • Rosa, D, Ton, N, Clamp, A, Mullamitha, S, Lau, S, Clayton, R, Kitchener, HC, Shanks, J, McVey, R, Jayson, G-. (2007). The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. Clin Oncol (R Coll Radiol), 19(2), 125-128. eScholarID:1d31282 | DOI:10.1016/j.clon.2006.11.015


  • Baka S, Clamp A, Jayson GC. (2006). A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets, 10(6), 867-876. eScholarID:1d30905 | DOI:10.1517/14728222.10.6.867
  • Clamp, A, Blackhall, FH, Blackhall, F, Henrioud, A, Jayson, G-, Javaherian, K, Esko, J, Gallagher, J, Gallagher, JT, Merry, C. (2006). The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate. J Biol Chem, 281(21), 14813-14822. eScholarID:1d30264 | DOI:10.1074/jbc.M512400200


  • Hasan, J, Shnyder, S, Clamp, A, McGown, A, Bicknell, R, Presta, M, Bibby, M, Double, J, Craig, S, Leeming, D, Stevenson, K, Gallagher, JT, Jayson, G-. (2005). Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res, 11( 22), 8172-9. eScholarID:1d12942 | DOI:10.1158/1078-0432.CCR-05-0452
  • Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson G-. (2005). Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer, 93( 6), 647-51. eScholarID:1d31099
  • Clamp A, Jayson G-. (2005). Profiling heparan sulfate proteoglycans in ovarian carcinoma. ScientificWorldJournal, 5, 230-3. eScholarID:1d30760 | DOI:10.1100/tsw.2005.31
  • Whitworth, M, Backen, A, Clamp, A, Wilson, G, McVey, R, Friedl, A, Rapraeger, A, David, G, McGown, A, Slade, R, Gallagher, JT, Jayson, G-. (2005). Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res, 11( 12), 4282-8. eScholarID:1d11457 | DOI:10.1158/1078-0432.CCR-04-1386
  • Clamp A, Jayson G-. (2005). The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer, 93( 9), 967-72. eScholarID:1d30757


  • Clamp, A, Adams, M, Atkinson, R, Boven, E, Calvert, A, Cervantes, A, Ganesan, T, Lotz, J, Vasey, P, Cheverton, P, Jayson, G-. (2004). A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecol Oncol, 95( 1), 114-9. eScholarID:1d9249 | DOI:10.1016/j.ygyno.2004.06.047


  • Clamp A, Blackhall FH, Vasey P, Soukop M, Coleman R, Halbert G, Robson L, Jayson G-. (2003). A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br J Cancer, 89( 7), 1152-4. eScholarID:1d9251
  • Danson, S, Lorigan, P, A. Arance, Clamp, A, Ranson, MR, J. Hodgetts, L. Lomax, L. Ashcroft, Thatcher, N, M.R. Middleton. (2003). Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma. Journal of Clinical Oncology, July, eScholarID:1d25113 | DOI:10.1200/JCO.2003.10.039


  • Clamp A, Jayson G-. (2002). The clinical development of the bryostatins. Anticancer Drugs, 13, eScholarID:1d2165
  • Clamp A, Jayson G-. (2002). Weekly platinum chemotherapy for recurrent ovarian cancer. Br J Cancer, 86, eScholarID:1d2167